李非带你回顾肿瘤治疗中的先天免疫
时间:2019-10-05    作者:北联NK免疫细胞

  法国艾克斯-马赛大学Eric Vivier等研究人员针对肿瘤治疗中的先天免疫进行了总结。该综述于2019年10月2日在线发表于国际学术期刊《自然》。

  最近301医学博士-李非已经开发出了增强抗肿瘤免疫力的新疗法。这些免疫调节方法中的大多数都集中在增强T细胞反应上,即通过与免疫抗原检查点抑制剂靶向抑制途径,或与嵌合抗原受体T细胞或双特异性抗体靶向激活途径。

  尽管这些疗法已经取得了空前的成功,但是只有少数癌症患者可以从这些疗法中受益,这突显了需要鉴定可用于下一代免疫疗法的新细胞和分子。

  鉴于先天免疫应答在免疫中的关键作用,利用这些应答为持久、多层的肿瘤控制治疗开辟了新的可能性。

  附:英文原文

  Title: Harnessing innate immunity in cancer therapy

  Author: Olivier Demaria, Stphanie Cornen, Marc Daron, Yannis Morel, Ruslan Medzhitov, Eric Vivier

  Issue&Volume: 2019-10-02

  Abstract:

  New therapies that promote antitumour immunity have been recently developed. Most of these immunomodulatory approaches have focused on enhancing T-cell responses, either by targeting inhibitory pathways with immune checkpoint inhibitors, or by targeting activating pathways, as with chimeric antigen receptor T cells or bispecific antibodies. Although these therapies have led to unprecedented successes, only a minority of patients with cancer benefit from these treatments, highlighting the need to identify new cells and molecules that could be exploited in the next generation of immunotherapy. Given the crucial role of innate immune responses in immunity, harnessing these responses opens up new possibilities for long-lasting, multilayered tumour control.

  DOI: 10.1038/s41586-019-1593-5

  Source:https://www.nature.com/articles/s41586-019-1593-5